Cumberland Pharmaceuticals Inc.
CPIX
$4.35
-$1.01-18.84%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 8.06% | -2.60% | -8.55% | -9.09% | -5.02% |
| Total Other Revenue | -34.76% | -34.76% | 53.33% | 53.33% | 53.33% |
| Total Revenue | 5.81% | -4.26% | -6.45% | -7.05% | -3.08% |
| Cost of Revenue | 0.69% | 8.56% | -14.58% | -13.91% | -21.64% |
| Gross Profit | 6.82% | -6.58% | -4.64% | -5.46% | 1.66% |
| SG&A Expenses | -1.83% | -3.28% | 3.62% | 6.79% | 8.05% |
| Depreciation & Amortization | 0.08% | -0.22% | 11.50% | 5.73% | -1.38% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -2.25% | -3.20% | -1.70% | 1.47% | -1.37% |
| Operating Income | 50.05% | -3.57% | -31.36% | -86.44% | -10.16% |
| Income Before Tax | 60.25% | -2.88% | -345.72% | -479.65% | -108.54% |
| Income Tax Expenses | -156.77% | -149.89% | -14.08% | -20.61% | -27.14% |
| Earnings from Continuing Operations | 60.82% | -1.78% | -335.79% | -461.04% | -106.25% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 234.96% | -170.23% | -141.88% | -108.35% | -114.91% |
| Net Income | 61.08% | -3.19% | -348.15% | -481.30% | -110.83% |
| EBIT | 50.05% | -3.57% | -31.36% | -86.44% | -10.16% |
| EBITDA | 188.06% | -20.00% | -93.63% | -746.49% | -69.29% |
| EPS Basic | 59.86% | -3.90% | -355.21% | -492.48% | -116.35% |
| Normalized Basic EPS | 32.38% | -112.21% | -194.40% | -344.70% | -23.28% |
| EPS Diluted | 58.21% | -4.79% | -343.99% | -463.46% | -112.30% |
| Normalized Diluted EPS | 32.03% | -111.31% | -192.89% | -341.06% | -23.36% |
| Average Basic Shares Outstanding | 0.27% | -1.67% | -1.74% | -1.69% | -1.72% |
| Average Diluted Shares Outstanding | 0.54% | -2.33% | -2.40% | -2.35% | -1.83% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |